TP53 and neoplasm: Next-generation sequencing (NGS) with the TSO500 panel (Illumina Inc., San Diego, CA, USA) identified pathogenic TP53 (VAF: 24%), and likely pathogenic GRM3 (VAF: 17%) and LRP1B (VAF: 46%) alterations along with low tumor mutational burden (TMB) and no microsatellite instability.